Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Medtronic
McKesson
Johnson and Johnson
Boehringer Ingelheim
Harvard Business School

Last Updated: June 29, 2022

Details for Patent: 8,372,872


✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,372,872 protect, and when does it expire?

Patent 8,372,872 protects ULORIC and is included in one NDA.

This patent has thirteen patent family members in eleven countries.

Summary for Patent: 8,372,872
Title:Methods for concomitant treatment of theophylline and febuxostat
Abstract: Co-administration of febuxostat and theophylline to a hyperuricemic patient suffering from gout is disclosed.
Inventor(s): Gunawardhana; Lhanoo (Pleasant Prairie, WI), Naik; Himanshu (Evanston, IL), Tsai; Max (Highland Park, IL)
Assignee: Takeda Pharmaceuticals U.S.A., Inc. (Deerfield, IL)
Application Number:13/295,696
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,372,872
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 8,372,872

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Takeda Pharms Usa ULORIC febuxostat TABLET;ORAL 021856-001 Feb 13, 2009 AB RX Yes No See Plans and Pricing See Plans and Pricing USE OF FEBUXOSTAT FOR THE MANAGEMENT OF HYPERURICEMIA IN PATIENTS SUFFERING FROM GOUT AND, WHEN USED WITH THEOPHYLLINE WITHOUT THE NEED FOR DOSE ADJUSTMENT OF THEOPHYLLINE See Plans and Pricing
Takeda Pharms Usa ULORIC febuxostat TABLET;ORAL 021856-002 Feb 13, 2009 AB RX Yes Yes See Plans and Pricing See Plans and Pricing USE OF FEBUXOSTAT FOR THE MANAGEMENT OF HYPERURICEMIA IN PATIENTS SUFFERING FROM GOUT AND, WHEN USED WITH THEOPHYLLINE WITHOUT THE NEED FOR DOSE ADJUSTMENT OF THEOPHYLLINE See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,372,872

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2011299153 See Plans and Pricing
Brazil 112013005792 See Plans and Pricing
Canada 2812034 See Plans and Pricing
China 103298466 See Plans and Pricing
European Patent Office 2613780 See Plans and Pricing
Spain 2532210 See Plans and Pricing
Hong Kong 1189170 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Baxter
Moodys
Dow
Medtronic
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.